Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENTINE-1 first-in-human study of DB-1418 in advanced or metastatic solid tumors
CTR20261416Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AVZO-1418 in Nonhematologic neoplasms, sponsored by AbbVie Inc.. Started May 2026; status: active.
02
Drugs
AVZO-1418
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261416.